Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04449198 · ClinicalTrials.gov registry record · Early Phase 1
Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1
A Early Phase 1 study of Type 1 Diabetes, sponsored by Augusta University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT04449198 is a Early Phase 1 study of Type 1 Diabetes that is actively recruiting participants, run by Augusta University. The registered enrollment target is 24 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04449198, a Early Phase 1 study of Type 1 Diabetes, is actively recruiting participants, sponsored by Augusta University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in people with type 1 diabetes.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Resveratrol
Study Locations (1)
Georgia
- Augusta University/Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-10-14 |
| Est. Completion | 2027-07-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04449198
The ClinicalTrials.gov registry entry for NCT04449198 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (97% lower). The listed sponsor is Augusta University, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04449198 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT04449198 about?
NCT04449198 is a clinical study titled "Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1". The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in people with type 1 diabetes.
What is the current status of trial NCT04449198?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2020-10-14. Estimated completion is 2027-07-01.
What conditions does trial NCT04449198 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT04449198?
The interventions under investigation include: Placebo (OTHER), Resveratrol (DRUG).
Who is sponsoring clinical trial NCT04449198?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04449198 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab
RECRUITING · Early Phase 1
-
Effect of C-peptide on Hypoglycemic Counterregulation
RECRUITING · Early Phase 1
-
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
COMPLETED · Early Phase 1
-
Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy
COMPLETED · Early Phase 1
-
Early Markers of Disease and Response to Therapy
COMPLETED · Early Phase 1
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.